Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2004 3
2005 3
2006 7
2007 4
2008 4
2009 6
2010 4
2011 4
2012 5
2013 5
2014 3
2015 17
2016 25
2017 20
2018 14
2019 17
2020 18
2021 21
2022 13
2023 17
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Results by year

Filters applied: . Clear all
Page 1
Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies.
Ambrosini G, Cordani M, Zarrabi A, Alcon-Rodriguez S, Sainz RM, Velasco G, Gonzalez-Menendez P, Dando I. Ambrosini G, et al. Among authors: velasco g. Cell Commun Signal. 2024 Jan 12;22(1):36. doi: 10.1186/s12964-023-01462-0. Cell Commun Signal. 2024. PMID: 38216942 Free PMC article. Review.
POTEE promotes breast cancer cell malignancy by inducing invadopodia formation through the activation of SUMOylated Rac1.
Martínez-López A, García-Casas A, Infante G, González-Fernández M, Salvador N, Lorente M, Mendiburu-Eliçabe M, Gonzalez-Moreno S, Villarejo-Campos P, Velasco G, Malliri A, Castillo-Lluva S. Martínez-López A, et al. Among authors: velasco g. Mol Oncol. 2024 Mar;18(3):620-640. doi: 10.1002/1878-0261.13568. Epub 2023 Dec 27. Mol Oncol. 2024. PMID: 38098337 Free PMC article.
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.
Albiges L, McGregor BA, Heng DYC, Procopio G, de Velasco G, Taguieva-Pioger N, Martín-Couce L, Tannir NM, Powles T. Albiges L, et al. Among authors: de velasco g. Cancer Treat Rev. 2024 Jan;122:102652. doi: 10.1016/j.ctrv.2023.102652. Epub 2023 Nov 4. Cancer Treat Rev. 2024. PMID: 37980876 Free article. Review.
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.
Grimm MO, Esteban E, Barthélémy P, Schmidinger M, Busch J, Valderrama BP, Charnley N, Schmitz M, Schumacher U, Leucht K, Foller S, Baretton G, Duran I, de Velasco G, Priou F, Maroto P, Albiges L; TITAN-RCC study group. Grimm MO, et al. Among authors: de velasco g. Lancet Oncol. 2023 Nov;24(11):1252-1265. doi: 10.1016/S1470-2045(23)00449-7. Epub 2023 Oct 13. Lancet Oncol. 2023. PMID: 37844597 Clinical Trial.
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
Romero-Laorden N, Lorente D, de Velasco G, Lozano R, Herrera B, Puente J, López PP, Medina A, Almagro E, Gonzalez-Billalabeitia E, Villla-Guzman JC, González-Del-Alba A, Borrega P, Laínez N, Fernández-Freire A, Hernández A, Rodriguez-Vida A, Chirivella I, Fernandez-Parra E, López-Campos F, Isabel Pacheco M, Morales-Barrera R, Fernández O, Villatoro R, Luque R, Hernando S, Castellano DC, Castro E, Olmos D. Romero-Laorden N, et al. Among authors: de velasco g. Eur Urol Oncol. 2023 Oct 12:S2588-9311(23)00207-9. doi: 10.1016/j.euo.2023.09.015. Online ahead of print. Eur Urol Oncol. 2023. PMID: 37838555
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.
El Zarif T, Nassar AH, Pond GR, Zhuang TZ, Master V, Nazha B, Niglio S, Simon N, Hahn AW, Pettaway CA, Tu SM, Abdel-Wahab N, Velev M, Flippot R, Buti S, Maruzzo M, Mittra A, Gheeya J, Yang Y, Rodriguez PA, Castellano D, de Velasco G, Roviello G, Antonuzzo L, McKay RR, Vincenzi B, Cortellini A, Hui G, Drakaki A, Glover M, Khaki AR, El-Am E, Adra N, Mouhieddine TH, Patel V, Piedra A, Gernone A, Davis NB, Matthews H, Harrison MR, Kanesvaran R, Giudice GC, Barata P, Farolfi A, Lee JL, Milowsky MI, Stahlfeld C, Appleman L, Kim JW, Freeman D, Choueiri TK, Spiess PE, Necchi A, Apolo AB, Sonpavde GP. El Zarif T, et al. Among authors: de velasco g. J Natl Cancer Inst. 2023 Dec 6;115(12):1605-1615. doi: 10.1093/jnci/djad155. J Natl Cancer Inst. 2023. PMID: 37563779 Free PMC article.
Case-control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study.
García-Donas J, de Velasco G, Madurga R, Chamorro J, Rosero D, Etxaniz O, Pérez-Gracia JL, Pinto Á, Cacho D, Barba M, Borrega P, Lázaro M, Rodriguez L, Villalobos L, García L, Cuellar A, Solís-Hernández MP, González A, Pernaut C, Rodríguez-Moreno JF. García-Donas J, et al. Among authors: de velasco g. Clin Transl Oncol. 2024 Mar;26(3):732-738. doi: 10.1007/s12094-023-03295-2. Epub 2023 Aug 9. Clin Transl Oncol. 2024. PMID: 37556096
Pseudokinases, Tribbles Proteins and Cancer.
Velasco G, Link W. Velasco G, et al. Cancers (Basel). 2023 Jul 9;15(14):3547. doi: 10.3390/cancers15143547. Cancers (Basel). 2023. PMID: 37509210 Free PMC article.
189 results